ArticleAntimicrobial agents and chemotherapy2023
Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections.
Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Pharmacokinetics, tolerability, and safety of TBI-223, a novel oxazolidinone, in healthy participants.Antimicrobial agents and chemotherapy · 2025Trial
- Clinical features of nontuberculous mycobacteria and diagnosis with nanopore targeted sequencing: a retrospective cohort study.Annals of clinical microbiology and antimicrobials · 2026Article
- The Structure, Properties, and Clinical Utility of Contezolid for Antituberculosis: A Narrative Review.Infectious diseases and therapy · 2026Review
- Article
- Deciphering linezolid-induced hematologic toxicity: Targeting TOP2A and TOP2B via its primary metabolite PNU142586.Science advances · 2025Article
- Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon.Acta pharmaceutica Sinica. B · 2025Review
- Context-specific inhibition of mitochondrial ribosomes by phenicol and oxazolidinone antibiotics.Nucleic acids research · 2025Article
- Toward better cures forClinical microbiology reviews · 2024Review
- Context-specific inhibition of mitochondrial ribosomes by phenicol and oxazolidinone antibiotics.bioRxiv : the preprint server for biology · 2024Article
- New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon?Pharmaceutics · 2024Review
- Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.Nature reviews. Drug discovery · 2024Review
- Treatment for non-tuberculous mycobacteria: challenges and prospects.Frontiers in microbiology · 2024Review
- Characterization ofMicrobiology spectrum · 2023Article
- Case report: Successful treatment with contezolid in a patient with tuberculous meningitis who was intolerant to linezolid.Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
New oxazolidinones are in clinical development for the treatment of tuberculosis and nontuberculous mycobacterial (NTM) infections, as a replacement for linezolid and tedizolid, which cause mitochondrial toxicity after prolonged treatment. Here, we carried out side-by-side measurements of mitochondrial protein synthesis inhibition and activity against clinically relevant mycobacterial pathogens of approved and novel oxazolidinones. We found a large range of selectivity indices suggesting TBI-223 and sutezolid as promising candidates against tuberculosis and NTM lung disease caused by Mycobacterium kansasii.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.